KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Five-Grass-Pollen Sublingual Immunotherapy Drops Are Efficacious and Well Tolerated in Adults: The RHAPSODY Phase III Trial.

Alain Didier, Ruta Gronskyte Juhl, Terrie Dalgaard, Antoine Chartier, Philippe Devillier

Allergy 81(6) 2123-2132

PMID41444697
PMCIDPMC13256269
DOI10.1111/all.70191
发表日期2025-12-24
入排依据:未发现恶性肿瘤人群证据。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:FIGURE 1:非 KM 图;FIGURE 2:非 KM 图;FIGURE 3:非 KM 图。
摘要

摘要

BACKGROUND: Tablet formulations of allergen extracts are widely recommended over other formulations for the sublingual immunotherapy (SLIT) of respiratory allergies. However, with adequate clinical trial evidence, SLIT (liquid) drop formulations may be a relevant allergy treatment option. METHODS: The RHAPSODY multinational, Phase III, parallel-group, double-blind, placebo-controlled, randomised clinical study of adults with moderate-to-severe, grass-pollen-induced allergic rhinoconjunctivitis (ARC) with or without asthma was conducted at 45 investigating centres in six European countries. Participants received 26 months of continuous treatment with active 5-grass-pollen SLIT drops or placebo. The primary efficacy endpoint was the average daily total combined score (TCS, comprising a symptom score and a rescue medication score) during the second peak grass pollen season (PGPS). RESULTS: Of the 445 randomised patients (mean ± standard deviation (range) age: 32.6 ± 9.9 (18-63); males: 55.1%), 389 completed the trial. The primary efficacy endpoint showed a statistically significant difference in favour of active treatment versus placebo (average difference in the daily TCS: 1.88 (95% CI: 0.60-3.17); relative difference 26.51% (95% CI: 9.42-40.55); p = 0.0036). The difference (0.17 points) in the average weekly Rhinitis Quality of Life Questionnaire score during the second PGPS in favour of the active treatment was clinically relevant but not statistically significant. The differences in efficacy were generally driven by the medication score, rather than the symptom score. Most adverse events were mild and local. CONCLUSIONS: RHAPSODY was the first well-powered clinical trial to show the positive risk-benefit ratio of 5-grass-pollen SLIT drops in adult participants with moderate-to-severe grass-pollen-induced ARC.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIGURE 1Patient disposition.
非 KM Figure
FIGURE 2The primary and key secondary efficacy endpoints in the 5‐grass‐pollen‐mix vs. placebo groups. (A) The TCS during the first and second PGPSs. (B) The RQLQ score in the second PGPS and the second EGPS. (C) The TCS during the first and second EGPSs.
非 KM Figure
FIGURE 3Changes from baseline in (A) the mean [95% CI] grass‐specific log 10 IgG 4 titre (mg A /L) and (B) the mean [95% CI] log10 grass‐specific IgE blocking factor in on‐treatment cases (FAS).
非 KM Figure